erlotinib hydrochloride has been researched along with Hand-Foot Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YS; Kim, HU; Kim, JI; Nam, KH; Park, J; Yun, SK | 1 |
| Clause, AL; Pieters, T; Vanderheyde, K | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Kruger, S; Laubender, RP; Märten, A; Modest, DP; Stintzing, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
1 trial(s) available for erlotinib hydrochloride and Hand-Foot Syndrome
| Article | Year |
|---|---|
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
2 other study(ies) available for erlotinib hydrochloride and Hand-Foot Syndrome
| Article | Year |
|---|---|
Hand-foot syndrome induced by erlotinib (Tarceva(Ⓡ) ).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Hand-Foot Syndrome; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Safety of reintroduction of erlotinib at low doses following hand-foot syndrome induced by erlotinib treatment for a Pancoast-Tobias tumour].
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Pancoast Syndrome; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2014 |